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Abstract 23 
Mycoplasma gallisepticum is among the economically most significant mycoplasmas causing 24 
production losses in poultry. 25 
Seven melt-curve and agarose gel based mismatch amplification mutation assays (MAMA) 26 
and one polymerase chain reaction (PCR) are provided in the present study to distinguish the 27 
M. gallisepticum vaccine strains and field isolates based on mutations in crmA, gapA, lpd, 28 
plpA, potC, glpK, and hlp2 genes. A total of 239 samples (M. gallisepticum vaccine and type 29 
strains, pure cultures and clinical samples) originating from 16 countries and from at least 30 
eight avian species were submitted to the presented assays for validation or in blind tests. 31 
Comparison of the data of 126 samples (including sequences available at GenBank) examined 32 
by the developed assays and a recently developed multi-locus sequence typing assay showed 33 
congruent typing results. The sensitivity of melt-MAMA assays varied between 10
1
-10
4
 34 
M. gallisepticum template copy number/reaction, while that of the agarose-MAMAs ranged 35 
between 10
3
 and 10
5
 template copy number/reaction and no cross-reactions occurred with 36 
other Mycoplasma species colonizing birds. The presented assays are also suitable to 37 
discriminate multiple strains in a single sample. 38 
The developed assays enable the differentiation of live vaccine strains by targeting two or 39 
three markers/vaccine strain; however, considering the high variability of the species, the 40 
combined use of all assays is recommended.  The suggested combination provides a reliable 41 
tool for routine diagnostics, due to the sensitivity and specificity of the assays, and that they 42 
can be performed directly on clinical samples and in laboratories with basic PCR equipment. 43 
 44 
 45 
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 48 
Introduction 49 
Infection with M. gallisepticum has a wide variety of clinical manifestations but the most 50 
important disease presentation is chronic respiratory disease in chickens and infectious 51 
sinusitis in turkeys resulting in reduced meat and egg production. Therefore M. gallisepticum 52 
is among the economically most significant mycoplasmas of poultry worldwide (1, 2). Like 53 
other pathogenic avian mycoplasmas, M. gallisepticum can be disseminated horizontally, but 54 
the major route of transmission is from infected breeder birds to progeny, and this is the prime 55 
consideration for international trade (2). 56 
Control programs for M. gallisepticum are based on maintaining commercial breeder stocks 57 
free of infection. In other cases, targeted antibiotic medication and vaccination are being 58 
evaluated as feasible options (2, 3). The commercially available agents for M. gallisepticum 59 
vaccination are bacterins, live vaccines and a M. gallisepticum antigen expressing 60 
recombinant fowl pox vaccine (4). Currently, the worldwide used live M. gallisepticum 61 
vaccine strains are the 6/85 (Nobilis
® 
MG6/85, MSD Animal Health), ts-11 (Vaxsafe
® 
MG, 62 
Bioproperties Pty Ltd.) and the F strain (Cevac
®
 MG-F, Ceva, Inc.). Strain 6/85 was 63 
developed by serial passages of a field isolate originating from USA (5, 6). The temperature-64 
sensitive vaccine strain ts-11 was selected from an Australian field isolate (strain 80083) after 65 
chemical mutagenesis (7). F strain was probably first isolated in 1956 in the USA (8), and it is 66 
a field strain with moderate virulence (9). Since live vaccines are used in many parts of the 67 
world, differentiation of M. gallisepticum vaccine strains from wild, virulent isolates has 68 
become essential in the control programs. 69 
The discrimination of vaccine strains from field isolates is a complicated challenge, as the 70 
genetics behind the attenuation of the vaccine strains are not well understood. Moreover, 71 
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reversion of the virulence of M. gallisepticum vaccine strains (10) or mixed infection with the 72 
vaccine and related strain types (11–13) can occur. 73 
Several attempts were made in the past to discriminate M. gallisepticum vaccine strains and 74 
field isolates, including DNA fingerprinting methods, like amplified fragment length 75 
polymorphism (AFLP) (14) and random amplified polymorphic DNA (RAPD) (15). 76 
However, these methods have low reproducibility and they require the isolation of the tested 77 
organisms. Sequence-based methods for the higher reproducibility and reliability, lower 78 
labour intensity and for the applicability on clinical samples have been designed also, such as 79 
gene-targeted sequencing (16), TaqMan assay (17) and high-resolution melt curve analysis 80 
(18–20). These techniques are usually tested on a very limited number of samples from a 81 
limited geographical region, need special equipment or highly expensive. Recently, 82 
polymerase chain reaction (PCR) tests have been developed for the differentiation of ts-11 83 
from field isolates (21), but these are not suitable in situations when multiple strains are 84 
present in a sample. For the genotyping of M. gallisepticum isolates a core genome multi-85 
locus sequence typing (MLST) system with improved discriminatory power have been 86 
established (22), but this method needs the previous isolation and whole genome sequence of 87 
the bacteria. Ultimately, a six-gene based MLST assay has been released also, which proved 88 
to be suitable for the discrimination of the ts-11, 6/85 and F vaccine strains (23). 89 
The current study describes the development and characterization of rapid and cost-effective 90 
PCR-based assays for the simultaneous discrimination of 6/85, ts-11 and F vaccine strains 91 
from field isolates. To better evaluate the system, the results were compared with the data of 92 
MLST analysis (23) and PCR assays described by Ricketts et al. (2016), and a total of 239 M. 93 
gallisepticum strains and clinical samples originating from 16 countries were examined. 94 
 95 
Materials and methods 96 
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M. gallisepticum strains and samples 97 
For the validation of the developed assays, vaccine strains 6/85 (Nobilis
® 
MG6/85, MSD 98 
Animal Health), ts-11 (Vaxsafe
® 
MG, Bioproperties Pty Ltd.) and F (Cevac
®
 MG-F, Ceva 99 
Inc.) were obtained from their commercial distributors. M. gallisepticum type strain (ATCC 100 
19610) was used as wild-type control in the assays. Fourteen M. gallisepticum field isolates 101 
were recovered from clinical submissions between 2010 and 2017 originating from Europe 102 
(Hungary, n=7; Romania, n=3; Ukraine, n=2; Czech Republic, n=1 and Spain n=1) (Dataset 103 
S1). The field isolates originated from tracheal swabs or lung samples of unvaccinated turkeys 104 
and chickens. Ethical approval and specific permission were not required for the study as all 105 
samples were collected by the authors during routine diagnostic examinations or necropsies 106 
with the consent of the owners. Isolation of the strains was performed by washing the tracheal 107 
swabs or the lung samples in 2 ml of Frey’s broth medium (pH 7.8) (24) and incubating at 37 108 
°C with 5% CO2 atmosphere. Filter cloning was used to gain pure cultures from the isolates. 109 
The DNA was extracted from the strains using the QIAamp DNA Mini kit (Qiagen, Inc., 110 
Hilden, Germany) according to the manufacturer’s instructions. All isolates were identified by 111 
qPCR targeting the mgc2 gene of M. gallisepticum (25). In order to exclude the presence of 112 
other, contaminant mycoplasmas in the cultures the DNA of the isolates was submitted to a 113 
universal Mycoplasma PCR system (26) followed by sequencing on an ABI Prism 3100 114 
automated DNA sequencer (Applied Biosystems, Foster City, CA), sequence analysis and 115 
BLAST search. 116 
A further 185 M. gallisepticum strains (cultures or DNA; Italy, n=75; Spain, n=42; United 117 
Kingdom, n=22; Israel, n=20; USA, n=7; Australia, n=6; The Netherlands, n=4; Germany, 118 
n=3; Portugal, n=2; Austria, n=1; France, n=1; Jordan, n=1 and Slovenia, n=1) and 36 DNA 119 
of clinical samples (Spain, n=17; Israel, n=8; Italy, n=6; Iraq, n= 3; Albania, n=1 and Jordan, 120 
n=1) were provided for blind test from sample collections (Dataset S1). The presence of M. 121 
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gallisepticum in the samples was checked with the PCR system described by Raviv and 122 
Kleven (25). Nuclease-free water was used as negative control in all PCR assays. 123 
 124 
Whole genome sequencing, sequence analysis and target selection 125 
M. gallisepticum genomic DNAs of vaccine strains 6/85 and ts-11 were extracted from 5 ml 126 
of logarithmic-phase broth cultures using a QIAamp DNA minikit (Qiagen, Inc.). Next-127 
generation sequencing was performed on Ion Torrent platform (New England BioLabs, 128 
Hitchin, United Kingdom) as previously described (27, 28). Reads were mapped to M. 129 
gallisepticum strain Rlow (GenBank Accession Number AE015450.2) as reference genome 130 
and annotated by Geneious software version 10.2.3 (29). The average numbers of reads and 131 
read lengths were 215,429 reads and 167.7 bp. The mean coverage was 45.7 and 31.3 for the 132 
whole genome of 6/85 and ts-11 strains, respectively. 133 
Candidate genes were selected according to previous publications (30–35). Candidate genes 134 
were retrieved from the genomes of M. gallisepticum ts-11, 6/85 and F vaccine strains 135 
(GenBank Acc. N.: NC_017503.1) and published M. gallisepticum genomes (strain S6, 136 
GenBank Acc. N.: NC_023030.2; strain Rlow GenBank Acc. N.: AE015450.2; strain Rhigh 137 
GenBank Acc. N.: NC_017502.1, house finch isolates, GenBank Acc. N.: NC_018412.1, 138 
NC_018409.1, NC_018406.1, NC_018407.1, NC_018408.1, NC_018410.1, NC_018411.1, 139 
NC_018413.1 and ts-11 re-isolates, GenBank Acc. N: MAFU00000000, MAFV00000000, 140 
MAFW00000000, MADW00000000, MATM00000000, MATN00000000, MAGQ00000000, 141 
MAGR00000000) and aligned by Geneious (29) (Dataset S1). The validity of single 142 
nucleotide polymorphisms (SNP) was confirmed by manual examination of the assembled 143 
sequences. Numbering of nucleotide positions was according to the individual genes of M. 144 
gallisepticum strain Rlow (GenBank Acc. N.: AE015450.2). SNPs and mutations present in 145 
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one of the M. gallisepticum vaccine strains (6/85, ts-11, F) but absent in other publicly 146 
available M. gallisepticum strains were selected for primer design. 147 
 148 
Assay design 149 
MAMA (Mismatch Amplification Mutation Assay) is a PCR-based technique used for SNP 150 
discrimination in many bacteria (36). In brief, the technique is based on SNP specific primers 151 
at the 3′ end, one being marked with an additional 15–20 bp long GC-clamp at the 5’ end. A 152 
single destabilizing mismatch at the 3′ end of each allele-specific primer enhances the 153 
discriminative capacity of the assay. The GC-clamp increases the melting temperature and the 154 
size of the amplicon as well. The temperature shift can be easily detected in the presence of 155 
intercalating fluorescent dye on a real-time PCR platform (Melt-MAMA) and the difference 156 
in the sizes of the amplicons can be observed in agarose gel electrophoresis (Agarose-157 
MAMA), which enable the differentiation of the SNP-specific genotypes. 158 
In the present study, MAMAs and a PCR (amplifying products with different length) were 159 
designed and tested for the detection of M. gallisepticum vaccine-specific alterations. Melt-160 
MAMA tests and the melt analysis of a PCR assay were optimized on Applied Biosystems 161 
Step-One Plus real-time PCR system with StepOne Software version 2.3 (Thermo Fisher 162 
Scientific, Waltham, MA, USA). Primer melting temperature (Tm) and general suitability 163 
were calculated using NetPrimer (Premier Biosoft International, Palo Alto, CA). The primer 164 
sequences and thermocycler parameters for the assays can be found in Table 1. 165 
PCR mixture of Melt-MAMAs and the PCR-6/85-crmA (analysed by melting) consisted of 2 166 
μl 5X Color-less GoTaq Flexi Buffer (Promega Inc., Madison, WI), 1 μl MgCl2 (25 mM), 0.3 167 
μl dNTP (10 mM, Qiagen Inc., Valencia, CA), 0.5 μl EvaGreen (20X, Biotium Inc., Hayward, 168 
CA), primers (10 pmol/ μl, according to Table 1), 0.08 μl GoTaq G2 Flexi DNA polymerase 169 
(5 U/μl; Promega Inc.), nuclease-free water and 1 μl DNA template with a final volume of 10 170 
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μl. Thermocycling parameters were 95 °C for 10 min, followed by 30 or 40 (according to 171 
Table 1) cycles of 95 °C for 15 s and 60 °C for 1 min. PCR products were subjected to melt 172 
analysis using a dissociation protocol comprising the steps 95 °C for 15 s, followed by 0.3 °C 173 
incremental temperature ramping from 60 °C to 95 °C. EvaGreen fluorescence intensity was 174 
measured at 525 nm at each ramp interval and plotted against temperature. All specimens 175 
were tested in duplicate. 176 
Agarose-MAMAs and the PCR-6/85-crmA (analysed by gel-electrophoresis) were performed 177 
in C1000™ Touch Thermal Cycler (Bio-Rad Laboratories, Inc., Berkeley, CA, USA) in 25 μl 178 
total volume containing 1 μl target DNA diluted in 5 μl 5X Green GoTaq Flexi Buffer 179 
(Promega Inc.), 2.5 μl MgCl2 (25 mM, Promeg Inc.), 0.5 μl dNTP (10 mM, Qiagen Inc.), 180 
primers (10 pmol/μl) according to Table 1, 0.25 μl GoTaq G2 Flexi DNA polymerase (5 U/μl; 181 
Promega Inc.) and nuclease-free water under the following PCR conditions: 95 °C for 5 min 182 
followed by 40 cycles at 95 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s. The final 183 
elongation step was performed at 72 °C for 5 min. Electrophoresis was carried out in 3% 184 
agarose gel (MetaPhor Agarose, Lonza Group Ltd., Basel, Switzerland) and a 20-bp DNA 185 
ladder (O'RangeRuler 20 bp, Thermo Fisher Scientific Inc.) was used as molecular weight 186 
marker. 187 
 188 
Validation of the assays 189 
Initially, the targeted mutations were selected according to in silico analysis of available 190 
M. gallisepticum whole genome sequences (19 isolates from GenBank and the 3 vaccine 191 
strains). For further evaluation, tests were challenged with the DNA of the live vaccine strains 192 
6/85, ts-11 and F, the type strain and with the DNA of M. gallisepticum field isolates 193 
originating from unvaccinated flocks (n=14, Dataset S1).  194 
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In order to test the sensitivity of the assays, tenfold dilutions of each genotype were used in 195 
the range of 10
6–100 copy number/μl. Template copy number was determined by a qPCR 196 
system targeting the mgc2 gene, which is present as a single copy in the M. gallisepticum 197 
genome (25). The tenfold dilution series of a synthetic sequence (500ng; gBlock, Integrated 198 
DNA Technologies Inc., Coralville, IA) was used as control for the template copy number 199 
determinations, which contain a 94 bp long fragment of the mgc2 gene (between nucleotides 200 
220622-220716, according to nucleotide numbering of the M. gallisepticum strain NCTC 201 
10115 at GenBank). The lowest template copy numbers yielding melting temperature (Tm) 202 
specific to the genotypes were considered the detection limit of the assays.  203 
The specificity of the assays was tested by involving the following avian mycoplasma species 204 
in the analysis: M. anatis (ATCC 25524), M. anseris (ATCC 49234), M. sp. 1220 (“M. 205 
anserisalpingitis”, ATCC BAA-2147), M. cloacale (ATCC 35276), M. columbinasale (ATCC 206 
33549), M. columbinum (ATCC 29257), M. columborale (ATCC 29258), M. gallinaceum 207 
(ATCC 33550), M. gallinarum (ATCC 19708), M. gallopavonis (ATCC 33551), M. iners 208 
(ATCC 19705), M. iowae (ATCC 33552), M. meleagridis (NCTC 10153) and M. synoviae 209 
(ATCC 25204) type strains. All M. gallisepticum vaccine strains (6/85, ts-11, F) were also 210 
included as control in all vaccine strain-specific assays. 211 
In order to assess the capability of the assays to identify mixed population of wild-type and 212 
vaccine strains in a single specimen, different template copy number combinations of the 213 
M. gallisepticum type strain and the vaccine strains (6/85, ts-11 or F) were tested in separate 214 
PCRs. The mixtures contained the type strain and one of the vaccine strains in the following 215 
combinations: constant template copy numbers (10
6 
copies/µl) of one strain was paired with a 216 
member of a series of 10-fold DNA dilutions (10
6
-10
3
 copies/µl) of the other strain and vice 217 
versa. 218 
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M. gallisepticum vaccine strains and the type strain were used in the stability testing of the 219 
mutations targeted by the designed assays. Each strain was passaged 10 times in Frey’s 220 
medium and submitted for the assays after DNA extraction. Genotype calls of the 10
th
 clones 221 
and the parent strains were compared. 222 
 223 
Blind tests, multi-locus sequence typing and strain-specific PCR 224 
Blind test of the developed assays was performed on the DNA of 185 M. gallisepticum 225 
isolates and 36 clinical samples originating from flocks of unknown vaccination status.  226 
Genetic diversity and relatedness to vaccine strains of the 14 M. gallisepticum strains used for 227 
the validation tests and 89 M. gallisepticum strains and clinical samples examined in the blind 228 
tests were previously determined by MLST analysis using six housekeeping genes (atpG, 229 
dnaA, fusA, rpoB, ruvB and uvrA) (23). MLST profiles of the live vaccine strains, the type 230 
strain and the 19 publicly available M. gallisepticum genomes has been defined also (23). 231 
Based on the genetic relatedness to vaccine strains four MLST profiles are presented in the 232 
current study: 6/85, ts-11, F and wild type (no relatedness to any of the live vaccine strains 233 
detected). Genotype calls of the presented assays were compared with genotype assignment of 234 
the MLST (Dataset S1). 235 
Samples which appeared to be ts-11 re-isolates by the developed MAMA tests and/or 236 
originating from Australia were further tested according to Ricketts et al. (21). In brief, the 237 
presence of three additional genes (vlhA3.04a, vlhA3.05 and mg03659) was investigated for 238 
the discrimination of field isolates from ts-11 vaccine strains. 239 
Accession numbers. Nucleotide sequences of M. gallisepticum amplicons included in the 240 
MLST were submitted to National Center for Biotechnology Information (NCBI) under 241 
GenBank Accession Numbers MH544230-MH544241 and MK288880- MK289516. 242 
 243 
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Statistical analyses 244 
Adjusted Rand co-efficient was used to determine the congruency of the assays in the 245 
comparisons. Values were calculated with the help of the online tool Comparing Partitions 246 
(http://www.comparingpartitions.info/?link=Tool). Samples which showed false negative 247 
results in any of the compared assays were excluded from the analyses. 248 
 249 
Results 250 
Sequence analysis and target selection 251 
For the differentiation of M. gallisepticum vaccine strains 6/85, ts-11 and F a total of 8, 15 252 
and 9 non-synonymous mutations were targeted with MAMA and PCR assays, respectively 253 
(data not shown). The number of assays was narrowed to two MAMAs and one PCR 254 
(examining the presence of a deletion) to strain 6/85, three MAMAs to strain ts-11 and two 255 
MAMAs to strain F. The targeted mutations are located in virulence associated genes (crmA, 256 
gapA, hlp2, lpd, plpA and glpK) or in the gene coding an ABC transporter protein (potC). 257 
Selection of the assays was performed according to preliminary examinations using the 258 
following criteria: 1) peaks of the melting curves of the vaccine and wild type strains were 259 
distinguishable; 2) the peak of the negative control did not overlap the peaks of the vaccine or 260 
the wild type strains; 3) the mutation was specific to the vaccine or vaccine re-isolates when 261 
all available samples with known vaccination status were tested. Amplicons containing the 262 
targeted mutations of the vaccine and the wild type strain are presented in Text S1. 263 
 264 
Validation of the assays 265 
The results of the validation tests of all selected assays are shown in Table 2. Melting 266 
temperatures and sizes of amplicons are listed in Table 2 and shown in Figure 1.  267 
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Detection limit of melt-MAMA assays varied between 10
1
-10
4
 template copy 268 
number/reaction, while agarose-MAMAs changed between 10
3
 and 10
5
 template copy 269 
number/reaction depending on the assay and the genotype. Negative controls or templates of 270 
other avian Mycoplasma species were either not amplified or generated non-specific products 271 
with melt-profiles differing from the profiles of the expected two allelic states. The non-272 
specific melting temperatures or band sizes should be omitted from further analyses. Assays 273 
differentiating one of the vaccine strains (6/85 or ts-11 or F) resulted in wild type specific 274 
amplicon when tested on the other two vaccines, discriminating M. gallisepticum vaccine 275 
strains from each other (Table 2). 276 
Considering the sensitivity of the assays in general, the tests showed similar sensitivity to the 277 
wild type and vaccine type M. gallisepticum DNA. Two assays specific for the ts-11 vaccine 278 
strain (MAMA-ts11-glpK and –potC) and one assay specific for the F vaccine (MAMA-F-279 
crmA) showed higher sensitivity to the wild type DNA and one assay specific for the 6/85 280 
vaccine strain (MAMA-6/85-crmA) showed higher sensitivity to the vaccine type DNA when 281 
mixtures of the wild and vaccine type DNA were tested (Table 2). Bimodal melting peaks at 282 
the specific melting temperatures or two amplicons with the specific band sizes indicated the 283 
presence of both M. gallisepticum variants (Figure 1).  284 
In vitro stability tests were based on the comparison of genotype calls of the 10
th
 clones of the 285 
three vaccine and the type strains and of the parent strains. Identical genotype calls were 286 
detected between clones and parent strains in all assays; however, it should be noted, that the 287 
test may not reflect completely the genetic stability of the strains under field conditions. 288 
 289 
Blind tests 290 
The quantity of M. gallisepticum DNA in the samples submitted for blind tests varied largely 291 
and showed wide range of cycle treshold (Ct) values in the mgc2 gene based qPCR (25) 292 
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(Dataset S1). In samples with higher Ct values (usually Ct values above 20 in the mgc2 gene 293 
based qPCR) the non-specific PCR product of the negative control was often visible beside 294 
the genotype specific amplicon in the developed assays, detected by real-time PCR as a 295 
bimodal peak or by agarose gel-electrophoresis as multiple bands (Figure 1B and D). The 296 
non-specific melting temperatures or band sizes were omitted from the analyses. 297 
In 11 cases results were evaluable only in one or none of the differentiating assays (Ct values 298 
above 28 in the mgc2 gene based qPCR (25)), thus these samples were omitted from further 299 
analysis. Further 9 DNA samples (Ct values above 20 in the mgc2 gene based qPCR (25)) 300 
showed false negative results in at least one of the following assays: MAMA-6/85-lpd (n=2), 301 
MAMA-ts11-plpA (n=6), MAMA-ts11-glpK (n=1), MAMA-ts11-potC (n=5) and MAMA-F-302 
crmA (n=3) (Dataset S1). The validity tests showed that PCR-6/85-crmA has the lowest 303 
sensitivity, and accordingly the highest number of false negative results was detected in the 304 
case of this assay (n=50, Ct values above 15 in the mgc2 gene based qPCR (25)).  305 
Assays MAMA-6/85-lpd, MAMA-6/85-gapA and PCR-6/85-crmA designed for the 306 
differentiation of 6/85 vaccine strain showed high congruency (range of adjusted Rand co-307 
efficients: 0.876-0.938). The results of two samples from Italy, namely IZSVE/2013/4693-4f 308 
and IZSVE/2014/6259-35f, showed discrepancy when tested with the developed assays. 309 
Sample IZSVE/2013/4693-4f was characterized as wild type M. gallisepticum by assay 310 
MAMA-6/85-gapA and 6/85 vaccine strain with the other two methods, while sample 311 
IZSVE/2014/6259-35f was discriminated as 6/85 vaccine with only MAMA-6/85-lpd 312 
(Dataset S1).  313 
MAMA-ts11-plpA, MAMA-ts11-glpK and MAMA-ts11-potC assays also showed high 314 
congruency (range of adjusted Rand co-efficients: 0.761-0.887). Excluding the differences 315 
caused by the distinct sensitivity of the assays, contradictory results were found in two cases. 316 
Sample 99179 from Australia was characterised as wild strain by MAMA-ts11-plpA and 317 
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vaccine strain by the remaining two assays. It is also notable, that sample IZSVE/2013/4693-318 
4f from Italy showed the mutations specific for ts-11 vaccine with assay MAMA-ts11-glpK, 319 
but was characterised as field strain with the rest of the assays.  320 
In the case of assays differentiating strain F from M. gallisepticum field isolates, only one 321 
strain (MYCAV391) of the 221 tested M. gallisepticum samples were characterised as 322 
vaccine type. The two tests (MAMA-F-hlp2 and MAMA-F-crmA) showed maximum 323 
congruency (adjusted Rand co-efficient: 1.000) (Dataset S1).  324 
 325 
Multilocus sequence typing and strain-specific PCR 326 
A total of 126 samples (including M. gallisepticum vaccine strains, the type strain, 19 327 
M. gallisepticum publicly available whole genome sequences, 14 strains used for validation 328 
and 89 samples used for blind test) were analysed by MLST. The eight developed typing 329 
methods showed high congruency with the MLST (range of adjusted Rand co-efficient: 330 
0.896-1.000), taking into consideration the sensitivity of the assays. 331 
Out of the three samples which showed incongruent results with the vaccine differentiating 332 
assays, IZSVE/2014/6259-35f showed the 6/85 vaccine type with only MAMA-6/85-lpd, and 333 
it was characterised as wild type strain by MLST.  IZSVE/2013/4693-4f showed the 334 
mutations specific for ts-11 vaccine with assay MAMA-ts11-glpK and for 6/85 vaccine with 335 
MAMA-6/85-lpd and PCR-6/85-crmA, while based on MLST analysis it proved to be a 336 
closely related field isolate to strain 6/85 (7/2636 nucleotide differences from 6/85 on 1 of 6 337 
examined genes). Sample 99179 showed the vaccine type by MAMA-ts11-glpK and MAMA-338 
ts11-potC assays, while based on MLST analysis it proved to be a closely related field isolate 339 
to strain ts-11 (10/2636 nucleotide differences from ts-11 on 3 of 6 examined genes).  340 
The ts-11 vaccine specific genotype was determined for strain K6216D based on in silico 341 
analysis of the targeted mutations in the strain’s whole genome sequence (GenBank Acc. N.: 342 
 o
n
 August 13, 2019 at University of Liverpool Library
http://jcm.asm.org/
D
ow
nloaded from
 
15 
 
MATM00000000). However, MLST analysis defined a unique sequence type (ST50) for this 343 
strain, differing in only one nucleotide from the ts-11 MLST profile (23). Similarly, strain 344 
IZSVE/2013/4957-D5d (MLST ST48), which originated from a chicken sample from Italy in 345 
2013 also differed only in one nucleotide from the ts-11 MLST profile (23). This strain 346 
showed the ts-11 genotype by the MAMA-ts11-glpK and MAMA-ts11-potC assays, but 347 
proved to be false negative by the MAMA-ts11-plpA assay. In the case of vaccine 6/85, the 348 
vaccine specific genotype was determined for strain IZSVE/2014/1779-12f in the blind test of 349 
the developed assays. This strain belonged to the MLST sequence type (ST13) most similar to 350 
the 6/85 MLST profile, showing only two nucleotide differences on one allele.   351 
According to the method of Ricketts et al. (2016) out of the 12 examined M. gallisepticum 352 
samples, all six Australian samples and one from Italy (IZSVE/2013/3185-5f) were 353 
characterised as ts-11 isolates, which results reveal poor agreement with the MLST and assays 354 
MAMA-ts11-plpA, MAMA-ts11-glpK and MAMA-ts11-potC (range of adjusted Rand co-355 
efficients: 0.198-0.327) (Dataset S1). 356 
 357 
Discussion 358 
M. gallisepticum infections have great impact on the poultry industry and vaccination is a 359 
cost-effective option to reduce economic losses. The use of M. gallisepticum live vaccines led 360 
to the need for a reliable technique which can differentiate vaccine strains from wild-type 361 
isolates. This is crucial in epidemiological investigations, vaccination, animal trading and 362 
eradication programs. 363 
DNA fingerprinting methods have limitations such as low reproducibility, lengthy procedure 364 
and the lack of comparable data between laboratories (14, 15). Other, sequence-based 365 
methods can only differentiate M. gallisepticum vaccine strains from strains of limited genetic 366 
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variability, or they are time- and resource-intensive processes or require the isolation of pure 367 
cultures (16–20, 22). 368 
This study revealed mutations in M. gallisepticum vaccine strains that are absent in Rlow and 369 
other publicly available M. gallisepticum field isolates. Targeted mutations are located in 370 
genes whose significance in virulence has already been investigated. Cytadhesins, encoded by 371 
gapA and crmA genes play a major role in M. gallisepticum host colonization and virulence 372 
(32). Gene hlp2, similar to hlp3, encodes cytadherence-associated protein (high molecular 373 
weight 2-like protein), while plpA encodes Pneumoniae-like protein A which is capable of 374 
binding fibronectin (35). The dihydrolipoamide dehydrogenase (encoded by lpd), a 375 
component of the pyruvate dehydrogenase complex is also identified as virulence-associated 376 
determinant, as it is required for in vivo growth and survival in the host (33). The glycerol 377 
kinase gene (glpK) has a role in H2O2 production thereby affecting host-cell cytotoxicity (30, 378 
37). PotC is the permease component of the ABC-type spermidine/putrescine transport 379 
system, however direct evidence of its role in virulence is lacking. Plasticity of the ABC 380 
transporter component genes is likely important for survival in the host environment (30). As 381 
numerous factors have a role in virulence and its alteration, several mutations were targeted 382 
by the assays designed in the present study. 383 
Real-time and conventional PCR assays were developed for the detection of these vaccine-384 
specific, candidate mutations and the assays were tested on 258 highly diverse 385 
M. gallisepticum strains and clinical samples (including vaccine strains, the type strain and 386 
whole genome sequences also). The diversity and genetic relatedness of 126 M. gallisepticum 387 
samples were previously investigated by MLST assay, determining strains with identical 388 
genotypes as 6/85, ts-11 or F vaccine strains (23). Considering the different sensitivities of the 389 
assays, congruent results were observed among the assays developed in this study for the 390 
differentiation of vaccine strains 6/85, ts-11 and F from field isolates and the MLST results as 391 
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well. However, evaluation of additional F strain re-isolates should further increase the 392 
reliability of the presented assays. Dissimilar genotype calls of the eight assays and 393 
comparison of the results with MLST sequence types indicate that MAMA-6/85-gapA is the 394 
most reliable assay to distinguish strain 6/85, while MAMA-ts11-plpA proved to be the most 395 
reliable assay for the discrimination of the vaccine ts-11 (Dataset S1).  396 
In the case of vaccine type ts-11, samples harbouring at least one SNP specific to strain ts-11 397 
and/or originating from the same country (Australia) as the parent strain of ts-11 vaccine were 398 
checked with PCR systems specific to ts-11 sequences described by Ricketts et al. (21). The 399 
disagreement was remarkable between the results of assays developed in the current study and 400 
the PCR systems of Ricketts et al. (21) as all five Australian wild-type samples showed the ts-401 
11 specific regions, while 5 of 6 samples containing ts-11 specific SNP lacked the ts-11 402 
specific sequences. The interpretation of negative results is difficult because besides the 403 
presence of the specific regions in the samples, the quality of the DNA and the sensitivity of 404 
the PCR systems also influence the results. Although detection limit is not published for the 405 
PCR systems of Ricketts et al. (21), according to our results, the detection limit of these 406 
assays was similar to that of the currently developed assays for the detection of the vaccine 407 
strain (10
3
 template copy number/reaction). As with the PCRs of Ricketts et al. (21), the 408 
developed assays were unable to discriminate ts-11 strains with reverted virulence as all non-409 
virulent and virulent ts-11 re-isolates contained the targeted mutations according to the 410 
sequences available at GenBank.  411 
It is noteworthy, that in the case of a ts-11 re-isolate with reverted virulence (strain K6216D, 412 
isolated from a progeny flock of a ts-11 vaccinated broiler flock which was not 413 
distinguishable from ts-11 vaccine strain by previous DNA sequence and RAPD analyses 414 
(10)) unique MLST ST was determined before (23). Likewise, the MLST system could 415 
distinguish other, closely related (differing at 1-10 positions in the examined 2636bp long 416 
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concatenated sequences) strains from vaccines ts-11 and 6/85, which showed the vaccine type 417 
(MLST ST difference: 1-2 positions) or incongruent results (MLST ST difference: 7-10 418 
positions) with the assays developed in this study. Among the currently available molecular 419 
tools, the combined use of the presented assays provides feasible option for the rapid 420 
differentiation of vaccine strains from field isolates with high approximation. 421 
The developed assays aim to support routine diagnostics by determining the successful 422 
vaccination of the animals or confirming M. gallisepticum free status of a flock. Based on the 423 
diagnostic application of previously established MAMAs for the discrimination of live 424 
Mycoplasma vaccine strains from wild strains (38), submitting the DNA pool of samples from 425 
a small group of animals (at least 4 pools from 20 birds/house) to test the presence of the 426 
vaccine/pathogen is the most appropriate method to reflect the status of a flock. In order to 427 
achieve the most definite results of the discrimination of M. gallisepticum vaccine and wild 428 
type strains, the combined use of all presented PCR tests is recommended. Non-specific 429 
melting temperatures or band sizes should be omitted from the analyses. During the 430 
interpretation of the results, congruent data indicate the presence of the vaccine strains. 431 
The developed method is highly specific, thus it is applicable directly on clinical samples, 432 
avoiding technical problems associated with isolation, which is particularly important in the 433 
case of mycoplasmas. However, due to the moderate sensitivity of certain assays, clinical 434 
specimens with lower DNA load may show false negative results, and in these cases strain 435 
isolation or enrichment may be required indeed. The presented assays are suitable for the 436 
detection of mixed infections and show similar sensitivity to the wild type and vaccine type 437 
strains. Further advantages of the assays are that they were all designed with the same thermal 438 
profile, allowing their simultaneous application, and they can be performed on basic real-time 439 
PCR platforms (without high-resolution melt function) and on conventional PCR equipment 440 
coupled with agarose gel electrophoresis. The strain-specific methods for 6/85, ts-11 and F 441 
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vaccines reported here represent convenient, rapid and cost-efficient tools for control 442 
programs against M. gallisepticum infections. 443 
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 570 
Figure legends 571 
Figure 1: Detection of A1306G substitution in gapA gene. y-axis: Derivative reporter, the 572 
negative first-derivative of the normalized fluorescence generated by the reporter during PCR 573 
amplification. x-axis: Temperature melt curve. A) Melting curves of the melt-MAMA 574 
showing melting temperatures of 6/85 vaccine strain (red line; Tm 80.3±0.1 ºC) and M. 575 
gallisepticum reference strain (ATCC 19610; blue line; Tm 76.0±0.6 ºC). Negative controls 576 
(grey lines) may show non-specific amplicons above Ct 33±2.9 (Tm 71.8±0.3 ºC) or no 577 
amplicons. B) Samples containing lower amounts of wild-type M. gallisepticum DNA can 578 
form a bimodal melting peak by the melt-MAMA: next to the wild type specific melting peak 579 
(sample IZSVE/2015/2062-4f with approximately 10
3 
template copy number/µl; 76.0±0.6 ºC), 580 
the peak of negative sample (Tm 71.8±0.3 ºC) also appears (green line). C) Samples 581 
containing mixed DNA of 6/85 vaccine (10
5
 template copy number/µl) and wild type strain 582 
(10
6
 template copy number/µl) can form bimodal melting peak by the melt-MAMA: next to 583 
the wild type specific melting peak (76.0±0.6 ºC), the peak of 6/85 (Tm 80.3±0.1 ºC) also 584 
appears (green line). D) PCR product sizes of MAMA-6/85-gapA in agarose gel. 585 
Electrophoresis was performed in 3% agarose gel (MetaPhor Agarose, Lonza Group Ltd., 586 
Basel, Switzerland) and a 20-bp DNA ladder (O'RangeRuler 20 bp, Thermo Fisher Scientific 587 
Inc.) was used as molecular weight marker (m). Line 1: non-specific amplicons in the 588 
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negative control below 60 bp, Line 2: 99 bp fragments specific for 6/85 vaccine strain, Line 3: 589 
wild-type strains yielded 85 bp fragments, Line 4: sample containing lower amount of wild-590 
type M. gallisepticum DNA (sample IZSVE/2015/2062-4f with approximately 10
3 
template 591 
copy number/µl), Line 5: sample containing mixed DNA of 6/85 vaccine (10
5
 template copy 592 
number/µl) and wild type strain (10
6
 template copy number/µl).  593 
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Tables 594 
Table 1: Primer sequences of assays for the differentiation of 6/85, ts-11 and F vaccine strains from field isolates designed in this study 595 
Vaccine Gene Mutation
a
 Assay name Primer name Primer sequence (5’→3’) 
Primer volume
 (μl)b Cycle number 
melt-
MAMA 
agarose 
MAMA 
melt-
MAMA 
agarose 
MAMA 
6/85 
lpd 
G1372T 
(A→S) 
MAMA-6/85-lpd 
lpd-1372-6/85 ggggcggggcggggGTTTTTTGTTRAAGTGGTTATAAATCGA 0.15 1 
40 40 lpd-1372-wt GTTTTTTGTTRAAGTGGTTATAAATAGC 0.6 4 
lpd-1372-con GAACAAGCAATTCACCCACACC 0.15 1 
gapA 
A1306G 
(R→G) 
MAMA-6/85-gapA 
gapA-1315-6/85 ggggcggggcggggGGTGTTTTTAGAACTAAATTTGAAATCG 0.15 1 
40 40 gapA-1315- wt GGTGTTTTYAGAACTAAATTTGAAAGCA 0.15 1 
gapA-1315-con ATAAAATACCGTATGGATAACCAACAG 0.15 1 
crmA 
48 nt del 
16 aa del 
PCR-6/85-crmA 
PCR-crmA-F TGCTGCTGCTAAACCTGGTGC 0.15 1 
40 40 
PCR-crmA-R GGAGCGGTTGGTTTTGGAGCA 0.15 1 
ts-11 
plpA 
C953G 
(T→S) 
MAMA-ts11-plpA 
plpA-971-ts11 ggggcggggcggggGCTTCTAGATGAGGTGTGATTGTGC 0.15 1 
30 40 plpA-971- wt GCTTCTAGATGAGGTGTGATTGAGG 0.15 4 
plpA-971-con GGATTATTACCTGAACTTGCCACAG 0.15 1 
glpK 
G67A 
(D→N) 
MAMA-ts11-glpK 
glpK-67-ts11 ggggcggggcggggACATCTTGTCGTTCAATCGTTTGTA 0.15 1 
40 40 glpK-67- wt ACATCTTGTCGTTCAATCGTTTCTG 0.15 1 
glpK-67-con GGAAAGTATTGCGTAAATTCGTTTTG 0.15 1 
potC 
C526G 
(Q→E) 
MAMA-ts11-potC 
potC-526-ts11 ggggcggggcggggATGAACCCAAATCTAATCTTAGCTTTAG 0.15 1 
30 40 potC-526- wt ATGAACCCAAATCTAATCTTAGCTTAAC 0.6 4 
potC-526-con GCGGGTGTTAAATAAGATAGAGTAATCT 0.15 1 
F 
hlp2 
G5542C 
(E→Q) 
MAMA-F-hlp2 
hlp2-5542-F ggggcggggcggggGTCTTAGTGTGGTTTTTTTAATCTTGTG 0.15 1 
40 40 hlp2-5542- wt GTCTTAGTGTGGTTTTTTTAATCTTCTC 0.15 1 
hlp2-5542-con GAAGTGCAAAAGAAATTAACTGATCTG 0.15 1 
crmA 
C2116G 
(Q→E) 
MAMA-F-crmA 
crmA-2116-F ggggcggggcggggACAACCATTCGGAACAACTCTCG 0.15 4 
40 40 crmA-2116- wt ACAACCATTCGGAACAACTCACC 0.15 1 
crmA-2116-con CTAATATTCTTAATTGATGAGAACTGATCAC 0.15 1 
a
 according to M. gallisepticum Rlow (GenBank Acc. N.: AE015450.2) nucleotide numbering, amino acid changes are indicated in parenthesis 596 
b
 Primer (10 pmol/μl) volume in 10 μl (melt-MAMA) and in 25 μl reaction mixture (agarose-MAMA) 597 
  598 
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Table 2: Results of the validation of assays designed in the present study based on the analyses of 18 M. gallisepticum strains 599 
Vaccine 
Assay 
name 
Genotype 
Tm 
(°C) 
Amplicon 
length 
(bp) 
NTC 
Sensitivity 
(template copy 
number/reaction)
a
 Cross 
reaction
b
 
Mixed samples (vaccine:wild type)
 
[template copy number/reaction] 
melt-
MAMA 
agarose 
MAMA 106:103 106:104 106:105 106:106 105:106 104:106 103:106 
v wt v wt 
6/85 
MAMA-
6/85-lpd 
6/85 79.8±0.1 102 Tm 72.4±0.1 °C 
Ct 29±0.2 
103 103 104 104 - 6/85 6/85 6/85 bm wt wt wt 
wt 76.5±0.3 88 
MAMA-
6/85-gapA 
6/85 80.3±0.1 99 -/Tm 71.8±0.3 °C 
Ct 33±2.9 
102 103 103 104 - 6/85 6/85 6/85 bm wt wt wt 
wt 76.0±0.6 85 
PCR-6/85-
crmA 
6/85 82.2±0.1 90 Tm 77.2±0.1 °C 
Ct 24.1±0.4 
104 104 104 105 - 6/85 6/85 6/85 6/85 bm wt wt 
wt 84.8±0.4 123-138 
ts-11 
MAMA-
ts11-plpA 
ts-11 82.2±0.0 82 
- 103 103 104 104 - ts-11 ts-11 bm bm wt wt wt 
wt 77.5±0.1 68 
MAMA-
ts11-glpK 
ts-11 79.3±0.1 94 -/Tm 61.3±0.0 °C 
Ct 32.5±0.7 
101 101 103 103 - ts-11 ts-11 ts-11 bm wt wt wt 
wt 76.3±0.1 80 
MAMA-
ts11-potC 
ts-11 77.6±0.1 106 Tm 72.8±0.3°C 
Ct 30.1±0.2 
104 103 104 104 - ts-11 ts-11 bm bm wt wt wt 
wt 74.4±0.1 92 
F 
MAMA-F-
hlp2 
F 78.0±0.1 102 -/ Tm 70.7±0.1 °C 
Ct 37.1±0.2 
103 102 103 103 - F F F bm wt wt wt 
wt 74.0±0.1 88 
MAMA-F-
crmA 
F 81.0±0.0 89 Tm 80.4, 72.6 °C 
Ct 31.8±0.9 
104 103 104 104 - F F bm wt wt wt wt 
wt 75.5±0.2 75 
Abbreviations: bm= bimodal peak indicating the presence of both genotypes in the sample; Ct= cyclic threshold; NTC= negative control; Tm= 600 
melting temperature; v= vaccine; wt= wild type; “-“=non-detected. 601 
a
 tested with both genotypes 602 
b
 tested with the following avian mycoplasma species: M. anatis (ATCC 25524), M. anseris (ATCC 49234), M. sp. 1220 (“M. anserisalpingitis”, 603 
ATCC BAA-2147), M. cloacale (ATCC 35276), M. columbinasale (ATCC 33549), M. columbinum (ATCC 29257), M. columborale (ATCC 604 
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29258), M. gallinaceum (ATCC 33550), M. gallinarum (ATCC 19708), M. gallopavonis (ATCC 33551), M. iners (ATCC 19705), M. iowae 605 
(ATCC 33552), M. meleagridis (NCTC 10153) and M. synoviae (ATCC 25204) type strain606 
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